GLP-1 Drugs Tame Brain's Craving Circuits for Alcohol
Clinical trials indicate semaglutide significantly reduces heavy drinking days by dampening brain reward signals. This article details the mechanism and latest study findings.
Oct 9, 2026
0 7
Science. Treatment. Real-world outcomes.
Stay Ahead of the GLP-1 Revolution
GLP-1 & Metabolic Health News delivers timely, evidence-based reporting on GLP-1 agonists, diabetes care, weight-management therapies, and metabolic research — clear, practical, and sourced from clinical experts.
Weekly briefings
Independently funded
Expert-vetted content
Latest Articles
New research, clinical updates, and patient stories
FDA Approves Mounjaro for Heart Risk in Type 2 Diabetes
The FDA approved Mounjaro to lower heart attack and stroke risk in diabetic patients. We analyze the SURPASS-CVOT data, regulatory significance, and what this means for metabolic health management.
Sep 28, 2026
0 14
Sleep Apnea Endotypes: Which Patients Respond Best to Zepbound?
New 2026 research reveals that Zepbound produces dramatic AHI reductions in a specific 'strong response' sleep apnea endotype. Learn who qualifies for these remission-level outcomes.
Sep 18, 2026
0 21
Most Read
Popular guides and in-depth analyses
GLP-1 Market Shifts Amid Patent Expiries and Trial Setbacks
The GLP‑1 landscape is undergoing a profound transformation as commercial realities collide with evolving clinical data. Early in 2026, Novo Nordisk issued a si...
May 13, 2026
0 59
GLP-1 Drugs Tame Brain's Craving Circuits for Alcohol
Clinical trials indicate semaglutide significantly reduces heavy drinking days by dampening brain reward signals. This article details the mechanism and latest study findings.
Oct 9, 2026
0 7
Mazdutide Surpasses Semaglutide in Head-to-Head Phase 3 Trial
Breakthrough Comparative Data EmergesInnovent Biologics has released compelling top-line results from its DREAMS-3 Phase 3 clinical trial, marking the first dir...
May 19, 2026
0 60
Explore Topics
Navigate by condition, treatment, or research area
REDEFINE-4: CagriSema Misses Non-Inferiority Against Tirzepatide
Novo Nordisk's Combination Therapy Delivers Strong Weight Loss, Yet Fails Head-to-Head Benchmark In a definitive test of mechanism-driven synergy, Novo Nordisk'...
May 25, 2026
0 75
Untitled
Jun 4, 2026
0 69
Beyond Efficacy: The Real-World Challenges of GLP-1 Adherence
In the rapidly evolving landscape of metabolic health, the arrival of dual GIP/GLP-1 receptor agonists and potent GLP-1 analogues has marked a therapeutic water...
Jun 1, 2026
0 66
Why GLP-1 & Metabolic Health News
Trusted, timely reporting on therapies and metabolism for clinicians, patients, and researchers — focused on evidence, context, and practical relevance.
Evidence-Based Reporting
Summaries and analyses grounded in peer-reviewed studies, clinical trials, and official guidelines.
Clinical Context
Actionable insights for clinicians on dosing, monitoring, side-effect management, and patient counseling.
Patient-Focused
Clear explanations, lived-experience perspectives, and resources to help patients navigate treatment choices.
Expert Contributors
Content informed by endocrinologists, researchers, pharmacists, and other specialists to ensure accuracy.
Policy & Access
Coverage of regulatory approvals, reimbursement developments, and market access that affect care delivery.
Newsroom Speed
Fast, careful coverage of breaking studies and guideline changes with follow-up analysis.
Free Access
Get our free newsletter
Weekly summaries, top stories, and practical tips delivered to your inbox at no cost.
Weekly research roundup
Treatment and safety highlights
Subscriber-only briefings
Stay Informed
Join clinicians, patients, and researchers who rely on concise, accurate coverage of GLP-1 therapies and metabolic health.
Subscribe FreeJoin the mailing list
Get new posts from GLP-1 & Metabolic Health News
Be the first to know when fresh articles are published.